Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507410 | 1.00 | HSD17B10 (0.35) | HSD17B10HDAC8SMN1; SMN2 | |
| SCHEMBL5511725 | 0.88 | HDAC8 (0.35) | HDAC8SMN1; SMN2 | |
| SCHEMBL4869919 | 0.88 | HDAC8 (0.35) | HDAC8SMN1; SMN2 | |
| SCHEMBL28777348 | 0.87 | HSD17B10 (0.36) | HSD17B10HDAC8SMN1; SMN2 | |
| SCHEMBL20488528 | 0.87 | HSD17B10 (0.33) | HSD17B10HDAC8SMN1; SMN2 | |
| SCHEMBL18591178 | 0.85 | HSD17B10 (0.39) | HSD17B10HDAC8SMN1; SMN2 | |
| SCHEMBL25930944 | 0.85 | HSD17B10 (0.39) | HSD17B10HDAC8SMN1; SMN2 | |
| SCHEMBL18555341 | 0.84 | HSD17B10 (0.38) | HSD17B10HDAC8SMN1; SMN2 | |
| SCHEMBL16647802 | 0.84 | HSD17B10 (0.38) | HSD17B10HDAC8SMN1; SMN2 | |
| SCHEMBL18578188 | 0.84 | HSD17B10 (0.38) | HSD17B10HDAC8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199106-B2 | Lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1644393-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012320-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | LCLAT1, NRDC, LAS1L | HSD17B10 1493/4885HDAC8 148/4885SMN1; SMN2 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.